Diego Alejandro Lucero

Dr. Diego Alejandro Lucero

Hospitalización, Clinica Cali, Santiago de Cali, Colombia
+1
orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Jhan Sebastian Saavedra T.Jhan Sebastian Saavedra T.
Jhan Sebastian Saavedra T.
MPMaría Virginia Pinzón-Fernández
María Virginia Pinzón-Fernández
HNHumberto Alejandro Nati-Castillo
Humberto Alejandro Nati-Castillo
VCValentina Cadena Correa
Valentina Cadena Correa
LMLuis Carlos López Montilla
Luis Carlos López Montilla
Juan S. Izquierdo-CondoyJuan S. Izquierdo-Condoy
Juan S. Izquierdo-Condoy
Sepsis is a life-threatening syndrome caused by a dysregulated host response to infection. It follows a dynamic course in which early hyperinflammation coexists and overlaps with progressive immune suppression, a process best described as immunodynamic disruption. Key mechanisms include extensive lymphocyte death, expansion of regulatory T cells, impaired antigen presentation, and persistent activation of inhibitory checkpoints such as programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte–associated protein 4 (CTLA-4). These changes reduce immune competence and increase vulnerability to secondary infections. Clinically, reduced expression of Human Leukocyte Antigen–DR (HLA-DR) on monocytes and persistent lymphopenia have emerged as robust biomarkers for patient stratification and timing of immunomodulatory therapies. Beyond the acute phase, many survivors do not achieve full immune recovery but instead develop a Persistent Immune Remnant, defined as long-lasting immune, metabolic, and endothelial dysfunction despite apparent clinical resolution. Recognizing PIR emphasizes the need for long-term monitoring and biomarker-guided interventions to restore immune balance. To integrate these observations, we propose the SIMMP–Sepsis model (Sepsis-Associated Persistent Multiorgan Immunometabolic Syndrome), which links molecular dysfunction to clinical trajectories and provides a framework for developing precision immunotherapies. This perspective reframes sepsis not only as an acute crisis but also as a chronic immunometabolic syndrome, where survival marks the beginning of active immune restoration.

29 May 2026 in Pathophysiology
Verified
Journal Article
Open access
PDF file
Jhan Sebastian Saavedra T.Jhan Sebastian Saavedra T.
Jhan Sebastian Saavedra T.
LCLady Viviana Acosta Castillo
Lady Viviana Acosta Castillo
ARAlexandra Montoya Rendon
Alexandra Montoya Rendon
DVDaniel Esteban Castro Valencia
Daniel Esteban Castro Valencia
DLDiego Alejandro Lucero
Diego Alejandro Lucero
Juan S. Izquierdo-CondoyJuan S. Izquierdo-Condoy
Juan S. Izquierdo-Condoy
Sepsis is a systemic disorder in which infection-induced inflammation progressively disrupts vascular homeostasis and drives organ dysfunction. This review reframes septic pathophysiology as a sequential and self-amplifying process centered on endothelial failure. Early activation of innate immune pathways by pathogen- and damage-associated molecular patterns promotes cytokine release, oxidative stress, and enzymatic degradation of the endothelial glycocalyx. Loss of this protective surface layer exposes endothelial cells to unbuffered inflammatory and mechanical injury, impairing mechanotransduction, increasing leukocyte and platelet adhesion, and destabilizing vascular barrier function. Subsequent disruption of intercellular junctions promotes capillary leakage, tissue edema, and impaired oxygen diffusion, while mitochondrial dysfunction and redox imbalance reduce endothelial repair capacity. In parallel, complement activation, neutrophil extracellular trap formation, platelet–leukocyte interactions, and loss of anticoagulant signaling shift the microvasculature toward a prothrombotic and proinflammatory state. These interconnected mechanisms culminate in microvascular incoherence, characterized by heterogeneous capillary flow, regional hypoxia, impaired oxygen extraction, and progressive organ failure despite apparent restoration of systemic hemodynamics. Within this framework, biomarkers such as syndecan-1, soluble thrombomodulin, angiopoietin-2, von Willebrand factor, and plasminogen activator inhibitor-1 are best interpreted as mechanistic readouts of glycocalyx shedding, endothelial injury, permeability imbalance, and thromboinflammatory activation. Understanding sepsis as an evolving endothelial pathophysiological process provides a coherent framework for integrating inflammation, vascular leakage, hypoxia, coagulation, and organ dysfunction while identifying mechanistic biomarkers that reflect distinct stages of microvascular collapse.

14 March 2026 in Medical Education & Clinical Practice
Verified
Journal Article
Open access
LMLuisa María Muñoz-Quiroga
Luisa María Muñoz-Quiroga
PPPaula Catalina Pérez-Sánchez
Paula Catalina Pérez-Sánchez
DLDiego Alejandro Lucero
Diego Alejandro Lucero
MDMichael Andres Davalos-Macias
Michael Andres Davalos-Macias
SVSara María Vieira-Rios
Sara María Vieira-Rios
JSJuan Santiago Serna-Trejos
Juan Santiago Serna-Trejos
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease characterized by heterogeneous clinical manifestations and driven by complex immunoinflammatory mechanisms, particularly activation of the type I interferon pathway. A subset of patients develops refractory disease, associated with increased symptom burden and significant impairment in quality of life. A narrative review of the literature was conducted using major biomedical databases, including original studies, clinical trials, systematic reviews, and relevant consensus statements. Evidence shows that, in addition to conventional therapies such as photoprotection, antimalarials, and immunosuppressive agents, targeted therapies have emerged with specific mechanisms of action, including Janus kinase inhibitors, type I interferon pathway blockers, and anti-BLyS antibodies, demonstrating efficacy in refractory CLE. These therapeutic advances support a shift toward more personalized treatment strategies, with the potential to improve clinical control and outcomes in patients with resistant disease.